N-PORT filing recap · April 2023
What did ARK Genomic Revolution ETF buy in April 2023?
Reported stock-position changes between this filing and the previous one. These are ARK Genomic Revolution ETF's own holdings, not the firm's.
Stock value
$1.86B
Positions
43
Estimated turnover
7.9%
Turnover is a proxy: verified trade-origin share changes valued at period-end and divided by average reported stock value. SEC holdings reports do not disclose execution dates or prices. Corporate actions and unreconciled activity are excluded.
Increased positions
TDOCTeladoc Health, Inc.$101.95Mreported value+17.9K shares+0.5%ACCDAccolade Inc$77.69Mreported value+329.0K shares+6.1%DNAGinkgo Bioworks Holdings, Inc.$58.43Mreported value+3.66M shares+8.3%CDNACaredx, Inc.$53.36Mreported value+200.7K shares+3.1%SLGCUSDSomalogic Inc$35.91Mreported value+1.98M shares+18.2%BFLYButterfly Network, Inc.$27.82Mreported value+3.39M shares+35.7%MASS908 Devices Inc.$26.18Mreported value+214.3K shares+5.9%PRMEPrime Medicine, Inc.$24.73Mreported value+369.8K shares+25.9%RPTXRepare Therapeutics Inc.$23.79Mreported value+199.6K shares+8.1%NRIXNurix Therapeutics, Inc.$22.00Mreported value+313.0K shares+15.9%CMPSCompass Pathways Plc$19.77Mreported value+321.9K shares+15.0%RXRXRecursion Pharmaceuticals, Inc.$16.55Mreported value+395.6K shares+12.9%CERSCerus Corporation$14.43Mreported value+501.5K shares+8.7%PSNLPersonalis, Inc.$12.97Mreported value+22.7K shares+0.4%GHGuardant Health, Inc.$12.77Mreported value+69.9K shares+14.1%NVTAInvitae Corp$11.03Mreported value+204.3K shares+2.6%